Early results from the CheckMate-648 clinical trial, which evaluated the 1 and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, sugge1st a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). These findings were presented at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting by Ian Chau, MD, Consultant Medical Oncologist, Gastrointestinal and Haemato-Oncology, Royal Marsden Hospital, Sutton, United Kingdom, and lead investigator of the trial. Read More ›

Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone. Read More ›

KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy. Read More ›

Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile. Read More ›

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer. Read More ›

Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement. Read More ›

Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer. Read More ›

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer. Read More ›

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer. Read More ›

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma. Read More ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: